Crinetics Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CRNX Nasdaq 2836 www.crinetics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Crinetics Pharmaceuticals, Inc.

Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Jan 21st, 2025 9:10 pm
Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential - Jan 17th, 2025 4:12 pm
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 10th, 2025 10:15 pm
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) - Jan 10th, 2025 12:00 pm
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Jan 6th, 2025 1:00 pm
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer - Dec 16th, 2024 1:00 pm
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 11th, 2024 1:44 am
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly - Dec 9th, 2024 1:00 pm
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences - Nov 15th, 2024 2:00 pm
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting - Nov 14th, 2024 9:05 pm
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) - Nov 14th, 2024 12:38 pm
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Nov 13th, 2024 7:18 am
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting - Nov 12th, 2024 9:07 pm
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 12th, 2024 9:05 pm
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 11th, 2024 9:05 pm
Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week - Oct 30th, 2024 2:29 pm
State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals - Oct 17th, 2024 7:09 pm
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 - Oct 16th, 2024 12:00 pm
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 10th, 2024 8:40 pm
Morning Movers: Arcadium Lithium surges after deal to be acquired - Oct 10th, 2024 12:57 pm